0950.HK

Unloved QualityAI neutral

Lee's Pharmaceutical Holdings Limited · Healthcare · Hong Kong · $80M cap · $38K/day traded

HKD 1.07 +0.9% · close 9 Nov · scored 10 Nov

Unloved Quality: Strong and cheap, but the market has not warmed to it.

92
Score
Get score and insider alerts
Quality
54
Value
95
Momentum
48

As of 10 Nov 2026, the MoatMap Score for Lee's Pharmaceutical Holdings Limited (0950.HK) is 92/100, ranked against 25,000+ stocks in 38 markets (Quality 54, Value 95, Momentum 48, each scored against its sector).

Does the score work? Each tenth of the ranking, tracked monthly. See the record →

P/E (TTM)
5.3x
peers 10.7x
ROE
3.3%
peers 6.4%
D/E
0.1x
peers 0.2x
Dividend %
5.3%
trailing yield
AI REVIEW

Lee's Pharmaceutical is a small Hong Kong-listed drug company focused on licensed and in-house products in China, trading at a low valuation with small insider purchases. There is little recent information on its pipeline or earnings trend, and Chinese drug price controls limit pricing power.

ABOUT LEE'S PHARMACEUTICAL HOLDINGS LIMITED

Read

Lee's Pharmaceutical Holdings Limited researches, develops, manufactures, and commercializes proprietary and licensed pharmaceutical products, focusing on cardiovascular, oncology, and gynecology. Its competitive advantage lies in focusing on niche therapeutic areas and a diversified pipeline of innovative drugs, leveraging both in-house R&D and strategic licensing. It is a specialty pharmaceutical company with a focus on specific therapeutic areas in China.

FINANCIAL SUMMARY (HKD)

Year20212022202320242025CAGRTTM
Revenue1.3B1.2B1.1B1.4B1.4B3.2%1.5B
EPS (HKD)3.380.090.030.160.16-53.6%0.20
Shares588.8M588.8M588.8M588.8M588.8M0.0%588.8M
Debt267.1M163.5M204.1M227.3M310.3M3.8%249.9M
Equity2.5B1.9B2.0B1.7B2.0B-4.5%—
Op CF210.7M283.6M110.1M242.0M332.9M12.1%383.2M
Inv CF-370.3M-256.1M-145.2M-190.2M-235.8M——
Fin CF61.0M-128.6M13.4M-2.0M35.6M——
PRICE (1Y) · HKD-9.7%
1.031.071.121.161.2025 Sep20 Oct9 Nov
SMA 50SMA 200

Price checkFinding a floorExperimental

No new 52-week low for 22 weeks, 11% above that low, but not back above a rising 50-day average.

SwingsBumpy

Swung more than 57% of stocks we rank over the past year (volatility 46% a year).

How this is worked out

The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.

The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.

What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.

Calm is not safe: a calm stock can still slide steadily.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
HKD 1.07
RSI (14)
50.0
52-Week Range-43.1% from high
Low HKD 0.9618High HKD 1.88

SCORE BREAKDOWN

Quality
54
ROIC
3.6%51.1
ROE
3.3%50.8
GP/Assets
23.6%52.7
Op. Margin
10.6%63.2
FCF/Assets
2.9%59.0
Piotroski
668.8
Int. Cover
7.7x57.8
D/E Ratio
0.13x58.6
Current Ratio
1.06x12.3
Value
95
P/E (TTM)
5.3x97.0
EV/EBITDA
1.4x98.2
P/FCF
6.2x90.4
P/B
0.3x98.6
P/S
0.4x93.9
Div Yield
5.3%91.7
Momentum
48
52W High %
57%35.7
RS 6M
4%61.9
SMA 50/200
0.98x54.6
EPS Rev 4W
0.0%51.2
EPS Rev 12W
-0.0%49.3
EPS Improve
-30%12.4
Q Growth
41%71.4

FUNDAMENTALS

Market Cap
$80M
P/E (Forward)
7.6x
Gross Margin
53.1%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 0950.HK are excluded.

TickerCompanyMkt CapScore
0950.HKLee's Pharmaceutical Holdings Limited(you)$80M92
0239.HKPak Fah Yeow International Limited$98M100
2348.HKDawnrays Pharmaceutical (Holdings) Limited$183M99
2161.HKJBM (Healthcare) Limited$160M83
2633.HKJacobson Pharma Corporation Limited$240M90
8049.HKJilin Province Huinan Changlong Bio-pharmacy Company Limited$189M100
3839.HKCPBIO Holding Company Limited$239M87
0897.HKWai Yuen Tong Medicine Holdings Limited$51M64
3613.HKBeijing Tong Ren Tang Chinese Medicine Company Limited$595M91
2005.HKSSY Group Limited$942M83

Peer medians: ROE 6.4% · P/E 10.7x · Gross margin 43.0%

Company Deep Dive

A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.

Request Deep Dive(50 Feathers)

Lee's Pharmaceutical Holdings Limited (0950.HK): Stock Score Summary

Lee's Pharmaceutical Holdings Limited (0950.HK) has a MoatMap Score of 92/100 based on Quality (54/100), Value (95/100), and Momentum (48/100) factor scores. Lee's Pharmaceutical is a small Hong Kong-listed drug company focused on licensed and in-house products in China, trading at a low valuation with small insider purchases. There is little recent information on its pipeline or earnings trend, and Chinese drug price controls limit pricing power.

Lee's Pharmaceutical Holdings Limited researches, develops, manufactures, and commercializes proprietary and licensed pharmaceutical products, focusing on cardiovascular, oncology, and gynecology. Its competitive advantage lies in focusing on niche therapeutic areas and a diversified pipeline of innovative drugs, leveraging both in-house R&D and strategic licensing. It is a specialty pharmaceutical company with a focus on specific therapeutic areas in China.

Director dealings

From 10 Nov 2025 to 10 Nov 2026, MoatMap's records hold no sales and 5 purchases of Lee's Pharmaceutical Holdings Limited (0950.HK) shares by its directors. The largest: Leelalertsuphakun Wanee bought 206,000 shares at HKD 1.15 on 17 Sep 2026 (about HKD 237K).

  • 17 Sep 2026: Leelalertsuphakun Wanee bought 206,000 shares at HKD 1.15 (about HKD 237K)
  • 5 Jun 2026: Leelalertsuphakun Wanee bought 81,500 shares at HKD 1.06 (about HKD 86K)
  • 4 Jun 2026: Leelalertsuphakun Wanee bought 200,000 shares at HKD 1.08 (about HKD 216K)
  • 29 May 2026: Leelalertsuphakun Wanee bought 41,500 shares at HKD 1.06 (about HKD 44K)
  • 28 May 2026: Leelalertsuphakun Wanee bought 200,000 shares at HKD 1.04 (about HKD 208K)
0950.HK insider filings, last 180 days

Key Financial Metrics

PriceHKD 1.07
Market Cap$80M
P/E (TTM)5.30
P/E (Forward)7.57
Price/Book0.29
Return on Equity3.3%
Return on Invested Capital3.6%
Debt/Equity0.13x
Gross Margin53.1%
Operating Margin10.6%
Revenue Growth14.6%
Dividend Yield5.3%
Free Cash Flow$13M

Lee's Pharmaceutical Holdings Limited operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (Hong Kong).

Frequently Asked Questions

What is Lee's Pharmaceutical Holdings Limited’s (0950.HK) MoatMap Score?
The MoatMap Score for Lee's Pharmaceutical Holdings Limited (0950.HK) is 92/100. It is a composite of Quality (54), Value (95), and Momentum (48), each scored against its sector. The composite is then ranked across MoatMap’s universe of 25,000+ stocks.
Does Lee's Pharmaceutical Holdings Limited have an economic moat?
Lee's Pharmaceutical Holdings Limited (0950.HK) has a Quality factor score of 54/100. Quality blends several measures of profitability and financial strength, led by gross profit to assets, return on invested capital and free cash flow to assets. A high score describes the financial record a durable advantage tends to leave; it does not prove a moat.
What sector is Lee's Pharmaceutical Holdings Limited in?
Lee's Pharmaceutical Holdings Limited (0950.HK) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (Hong Kong).